Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Levy, 2002, Long-term trends in the incidence of and survival with heart failure, N Engl J Med, 347, 1397, 10.1056/NEJMoa020265 Kaklamani, 2003, Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?, Clin Breast Cancer, 4, S26, 10.3816/CBC.2003.s.012 Zambetti, 2001, Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation, J Clin Oncol, 19, 37, 10.1200/JCO.2001.19.1.37 Doyle, 2005, Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study, J Clin Oncol, 23, 8597, 10.1200/JCO.2005.02.5841 Basar, 2014, Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?, Pediatr Hematol Oncol, 31, 237, 10.3109/08880018.2013.851753 Jurcut, 2008, Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer, J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr, 21, 1283, 10.1016/j.echo.2008.10.005 Mercuro, 2007, Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers, Oncologist, 12, 1124, 10.1634/theoncologist.12-9-1124 Dorup, 2004, Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function, Heart Br Card Soc, 90, 1214, 10.1136/hrt.2003.027516 Cardinale, 2006, Troponins in prediction of cardiotoxic effects, Ann Oncol, 17, 173, 10.1093/annonc/mdj003 Cardinale, 2006, Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition, Circulation, 114, 2474, 10.1161/CIRCULATIONAHA.106.635144 Perik, 2005, Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors, Anticancer Res, 25, 3651 Meinardi, 2002, Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques, Heart Br Card Soc, 88, 81, 10.1136/heart.88.1.81 Piccart, 2001, Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J Clin Oncol, 19, 3103, 10.1200/JCO.2001.19.12.3103 De Azambuja, 2009, Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study, J Clin Oncol, 27, 720, 10.1200/JCO.2008.17.2155 Gottdiener, 2004, American Society of Echocardiography recommendations for use of echocardiography in clinical trials, J Am Soc Echocardiogr, 17, 1086 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002, ATS statement: guidelines for the six-minute walk test, Am J Respir Crit Care Med, 166, 111, 10.1164/ajrccm.166.1.at1102 Borg, 1982, Psychophysical bases of perceived exertion, Med Sci Sports Exerc, 14, 377, 10.1249/00005768-198205000-00012 Lipshultz, 2013, Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association, Circulation, 128, 1927, 10.1161/CIR.0b013e3182a88099 Armenian, 2014, Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors, Clin Cancer Res, 20, 6314, 10.1158/1078-0432.CCR-13-3490 Chow, 2014, Individual prediction of heart failure among childhood cancer survivors, J Clin Oncol Pinder, 2007, Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer, J Clin Oncol, 25, 3808, 10.1200/JCO.2006.10.4976 Fumoleau, 2006, Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results, Ann Oncol, 17, 85, 10.1093/annonc/mdj034 Jiji, 2012, Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs, J Nucl Cardiol, 19, 377, 10.1007/s12350-012-9512-2 Wassmuth, 2001, Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—a pilot study, Am Heart J, 141, 1007, 10.1067/mhj.2001.115436 Drafts, 2013, Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease, JACC Cardiovasc Imaging, 6, 877, 10.1016/j.jcmg.2012.11.017 Kumar, 2012, Doxorubicin-induced cardiomyopathy 17 years after chemotherapy, Tex Heart Inst J Tex Heart Inst St Lukes Episcop Hosp Tex Child Hosp, 39, 424 Okumura, 2000, Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity, Acta Haematol, 104, 158, 10.1159/000046508 Bautmans, 2004, The six-minute walk test in community dwelling elderly: influence of health status, BMC Geriatr, 23, 6, 10.1186/1471-2318-4-6